Larvol Delta - CNS-Pharmaceuticals-Doses-First-Group-of-Patients-with-Berubicin-an-FDADesignated-Fast-Track-Drug-Candidate-in-the-Potentially-Pivotal-Study-for-the-Treatment-of-Glioblastoma-Multiforme-GBM

berubicin (RTA 744) - CNS Pharma, WPD Pharma

https://www.prnewswire.com/news-releases/cns-pharmaceuticals-doses-first-group-of-patients-with-berubicin-an-fda-designated-fast-track-drug-candidate-in-the-potentially-pivotal-study-for-the-treatment-of-glioblastoma-multiforme-gbm-301388673.html

Sep 30, 2021

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next